Comparison of seven healthcare databases in EU countries using a standardized methodology; a descriptive study on the exposure to calcium-channel blockers

de Groot MCH1, van den Ham HA1, De Bruin ML2, Afonso A1, Huerta Alvarez C1, Gill M2, Requena G3, Hesse U4, Falberg Renn P4, Souverein PC1, Alvarez Y5, Slattery J6, Rottenkolber M7, Schmiedl S7,8, Van Dijk L1,9, Schlienger RG10, Reynolds R11, Klungel OH1, Grimaldi-Bensouda L12


Acknowledgements and statements: The research leading to these results received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicines Initiative (www.imi.europa.eu) under Grant Agreement n° 115004. The research leading to these results was conducted as part of the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, www.imi-protect.eu) which is a public-private partnership coordinated by the European Medicines Agency.

Conflict of interest: The department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, has received unrestricted research funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Insurance Board (CVZ), the Royal Dutch Association for the Advancement of Pharmacy (KNMP), the private-public funded Top Institute Pharma (www.topharma.nl), includes co-funding from universities, government, and industry; the EU Innovative Medicines Initiative (IMI), EU 7th Framework Program (FP7), the Dutch Medicines Evaluation Board, the Dutch Ministry of Health and industry (including SmithKline, Pfizer, others).